• 1
    Lee TN, Alborn WE, Knierman MD, Konrad RJ. The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochem. Pharmacol. 2006; 72: 71018.
  • 2
    Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106: 24653.
  • 3
    Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal Physiol. 2006; 290: F21422.
  • 4
    Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris D. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int. 2005; 68: 3918.
  • 5
    Kraynak AR, Storer RD, Jensen RD et al. Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol. Appl. Pharmacol. 1995; 135: 27986.
  • 6
    Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006; 69: 7380.
  • 7
    Ma G, Allen TJ, Cooper ME, Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int. 2004; 66: 109098.
  • 8
    Cooper ME, Allen TJ, Macmillan P, Bach L, Jerums G, Doyle AE. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am. J. Hypertens. 1988; 1: 510.
  • 9
    Davis BJ, Johnston CI, Burrell LM et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003; 46: 96171.
  • 10
    Allen TJ, Cao Z, Yousef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 1997; 46: 161218.
  • 11
    Kang MJ, Ingram A, Ly H, Thai K, Scholey JW. Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. Kidney Int. 2000; 58: 167785.
  • 12
    Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003; 63: 20916.
  • 13
    Lassila M, Seah KK, Allen TJ et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: Role of advanced glycation end products. J. Am. Soc. Nephrol. 2004; 15: 212538.
  • 14
    Keppler A, Gretz N, Schmidt R et al. Plasma creatinine determination in mice and rats: An enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int. 2007; 71: 748.
  • 15
    Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am. J. Physiol. Renal Physiol. 2004; 286: F59096.
  • 16
    Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 1990; 39: 118290.
  • 17
    Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrol. Dial. Transplant. 2004; 19: 298796.
  • 18
    Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989; 32: 3268.
  • 19
    Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005; 54: 262837.
  • 20
    Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 2006; 21: 2399405.
  • 21
    Lassila M, Jandeleit-Dahm KA, Seah KK et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 2005; 16: 36373.
  • 22
    Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998; 54: 34352.
  • 23
    Hartner A, Cordasic N, Klanke B, Wittmann M, Veelken R, Hilgers KF. Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am. J. Physiol. Renal Physiol. 2007; 292: F82027.